First patients treated with CLS TRANBERG-system in the clinical study at Toronto General Hospital, Canada

Clinical Laserthermia Systems AB (publ) announces that the first two patients are treated in the clinical study at Toronto General Hospital in Toronto, Canada, where the TRANBERG®|Thermal Therapy Systemis included.  The treatments were carried out according to the study protocol and without any problems. The study at Toronto General Hospital is, as previously announced, about treatment of prostate cancer with MRI-guided focal laser ablation (FLA). The hospital has initiated the study which includes 25 patients. The objective is to evaluate safety and efficacy in treatment of prostate cancer with MRI- guided focal laser ablation. 

- The treatments went as planned and the patients are, according to the hospital, well. A part from important data on how our products perform in MRI-guided focal laser ablation, we receive important user feedback from the doctor carrying out the treatment procedure. They are very positive not least to our fiber, but also to the flexibility and ease-of-use of our system. The hospital in Toronto has a knowledgeable multidisciplinary team and I’m looking forward to continue the collaboration in this study, said Karin Peterson, Chief Product Officer of CLS. 

The clinical study will go on for 24 months and include men with early stage prostate cancer, who have not undergone radiation or hormone treatment. Toronto General Hospital will register the study at clinicaltrials.gov.

This pressrelease has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se